• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

    7/31/24 4:01:00 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALXO alert in real time by email
    • Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial

    • Evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3% compared to 26.6% for the control arm and demonstrated a median duration of response of 15.7 months compared to 7.6 months in the full trial population
    • In the pre-specified population of patients with fresh HER2-positive biopsies, evorpacept combination showed the greatest benefit with ORR of 54.8% vs. 23.1% in the control, suggesting HER2-expression strongly correlates with evorpacept efficacy and validating its mechanism of action
    • Company to host conference call and webcast today at 4:30 PM EDT

    SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced topline data from its Phase 2 ASPEN-06 clinical trial. The trial demonstrated clinically meaningful improvements in overall response rate and duration of response among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.

    "The topline results from the ASPEN-06 clinical trial confirm the robust response that evorpacept can deliver, generating a clinically meaningful impact on key measures of anti-cancer activity for patients with gastric cancers and continuing to surpass benchmarks in the field," said Jason Lettmann, chief executive officer at ALX Oncology. "Additionally, they provide valuable insight beyond the interim data previously reported, offering a more conclusive look at the impact of evorpacept and identifying the most responsive patient population. Importantly, the level of clinical benefit seen in this trial provides support for developing evorpacept in combination with anti-cancer antibodies in additional tumor types and drives ALX's development strategy."

    ASPEN-06 is a randomized, multi-center, international trial evaluating evorpacept, ALX Oncology's investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel (collectively, TRP) against TRP alone for the treatment of patients with HER2-positive gastric/GEJ cancer, where all patients had received an anti-HER2 agent in prior lines of therapy. Patients in the trial (N=127) were generally well-balanced across arms based on pre-specified stratification factors including line of therapy, prior ENHERTU® (fam-trastuzumab deruxtecan-nxki) use, Asia region, tumor location (GC or GEJ), HER2 expression level (IHC3+ or IHC2+/ISH+) and HER2-positive biopsy (fresh or archival).

    The trial's primary endpoint is overall response rate (ORR). Key secondary endpoints are safety, median duration of response (mDOR), progression-free survival (PFS) and overall survival (OS).

    Key Phase 2 ASPEN-06 Clinical Trial Topline Results:

    • In the full intent-to-treat population (N=127), the addition of evorpacept to TRP demonstrated an ORR of 40.3% compared to the TRP control ORR of 26.6%
    • In patients with fresh HER2-positive biopsies (n=48), evorpacept plus TRP demonstrated an ORR of 54.8% compared to 23.1% for the TRP control
    • Median duration of response (DOR) in the evorpacept arm was 15.7 months [95% CI: 11.0; NE] compared to the TRP control of 7.6 months [95% CI: 6.3; NE] in the full intent-to-treat population
    • Secondary endpoints of PFS and OS were immature at the time of analysis
    • Evorpacept in combination with TRP was generally well tolerated and consistent with TRP control

    "By meeting our clinically meaningful and pre-specified threshold of greater than 10% difference in response between the evorpacept treatment and control arms, these new data validate the mechanism of action and potential clinical utility of evorpacept for patients. Notably, this is now the first CD47 blocker to demonstrate clinical benefit and a well-tolerated safety profile in a randomized trial," said Sophia Randolph, M.D., Ph.D., chief medical officer at ALX Oncology. "ASPEN-06 also provides valuable insights into responding patient populations and the importance of HER2 target expression that will inform our clinical program. These data represent a significant advancement for immuno-oncology."

    The ASPEN-06 full data set will be submitted for presentation at an upcoming medical conference.

    The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to evorpacept for the second-line treatment of patients with HER2-positive gastric or GEJ carcinoma. Additionally, both the FDA and European Commission have granted Orphan Drug Designation for this indication.

    Conference Call and Webcast on July 31 at 4:30 PM EDT

    The Company will host a conference call and webcast today at 4:30 PM EDT. To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally) at least 10 minutes prior to the start time and refer to conference ID 9637001. The link to the live webcast of the conference call will be posted in the News & Events section (see "Events") of the Company's website at www.alxoncology.com. An archived replay will be accessible for 90 days following the event.

    About the ASPEN-06 Phase 2 Clinical Trial

    ASPEN-06 is a randomized Phase 2 (open-label) / Phase 3 (double-blinded), multi-center, international trial of patients with second- or third-line metastatic HER2-overexpressing gastric/GEJ adenocarcinoma that progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy (NCT05002127). HER2 status was determined by an FDA-approved test in the most recent gastric/GEJ cancer tissue sample. The primary analysis of the full intent-to-treat population included all randomized patients whose HER2 status was based on a tissue sample obtained at any time. An additional primary analysis was conducted on patients who had a recent HER2-positive tissue sample after prior anti-HER2 therapy ("fresh biopsy"). While trastuzumab is currently approved in combination with cisplatin and capecitabine/5-FU for HER2-positive gastric/GEJ cancers, it is not approved in combination with standard-of-care CYRAMZA + paclitaxel. The Phase 2 portion of the ASPEN-06 trial enrolled 127 patients. To determine the activity of evorpacept + trastuzumab + CYRAMZA + paclitaxel, in the Phase 2 portion of ASPEN-06, patients were randomized to receive either a four-drug combination regimen (evorpacept + trastuzumab + CYRAMZA + paclitaxel) or a three-drug combination regimen (trastuzumab + CYRAMZA + paclitaxel). This design enabled the assessment of evorpacept's contribution to the standard of care plus trastuzumab and to global standard of care, CYRAMZA + paclitaxel.

    About ALX Oncology

    ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47-binding domain with an inactivated, proprietary Fc domain. To date, evorpacept has been dosed in over 500 subjects and has demonstrated promising activity and favorable tolerability profile across a range of hematologic and solid malignancies in combination with various leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies, antibody-drug conjugates and PD-1/PD-L1 immune checkpoint inhibitors.

    Evorpacept's Unique Profile: Anchored by a Rational Design and Triple Development Pillars

    Rationally engineered with an inactive Fc effector function, evorpacept's clinical data to date have demonstrated a substantially improved safety profile over other anti-CD47 molecules in the clinic with an active Fc (i.e., binding the Fc gamma receptor on macrophages). This best-in-class safety profile allows for higher dosage with minimal overlapping toxicity in the combination treatment setting. CD47 expressed on cancer cells binds to its receptor SIRP alpha, which is predominantly expressed on two cell types: macrophages and dendritic cells. The Company's pipeline of therapeutic candidates with standard-of-care agents include:

    • Anti-cancer antibodies and ADCs (the "don't eat me" signal): evorpacept enables Fc-mediated antibody-dependent phagocytosis by macrophages in combination with anti-cancer antibodies (e.g., Herceptin®) and ADCs (e.g., PADCEV and ENHERTU®) with an active Fc domain, which is otherwise impaired by CD47 expression on cancer cells binding to SIRP alpha on macrophages. Additionally, ADCs target the delivery of a chemotherapeutic payload to tumor cells to exert cytotoxic effects.
    • PD-1/PD-L1 immune checkpoint inhibitors (the "don't activate T-cells" signal): evorpacept enables T-cell activation by dendritic cells that are constitutively inhibited by CD47 expression on cancer cells binding to SIRP alpha on dendritic cells. Activated dendritic cells present neoantigens to T cells that once activated will kill cancer cells when the PD-1/PD-L1 inhibitory interaction is blocked by T-cell checkpoint inhibitors.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology's filings with the Securities and Exchange Commission ("SEC"), including ALX Oncology's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.



    Company Contact: Caitlyn Doherty, Manager, Corporate Communications, ALX Oncology, [email protected], (650) 466-7125
    
    Investor Contact: Malini Chatterjee, Ph.D., Blueprint Life Science Group, [email protected], (917) 330-4269
    
    Media Contact: Audra Friis, Sam Brown, Inc., [email protected], (917) 519-9577

    Primary Logo

    Get the next $ALXO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALXO

    DatePrice TargetRatingAnalyst
    3/6/2025$2.00 → $3.00Hold → Buy
    Jefferies
    12/19/2024$12.00 → $2.00Buy → Hold
    Jefferies
    3/8/2024$10.00 → $14.00Buy → Hold
    Stifel
    12/8/2023$8.00 → $18.00Hold → Buy
    Jefferies
    3/1/2022$60.00 → $36.00Buy
    Stifel
    12/22/2021$65.00 → $25.00Buy → Hold
    Jefferies
    9/30/2021$106.00Buy
    Stifel
    More analyst ratings

    $ALXO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

      SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      5/15/25 4:15:24 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

      SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      5/15/25 4:05:22 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ALX Oncology Holdings Inc.

      10-Q - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

      5/8/25 4:01:21 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by SVP, FINANCE AND CAO Pinto Shelly

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:29:19 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Sandler Alan B.

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:19:34 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Shantharam Harish

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:16:28 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Financials

    Live finance-specific insights

    See more
    • ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

      SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives. ALX Oncology's lea

      5/2/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

      SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.  The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives.

      2/27/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

      Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trialGreatest benefit observed among patients with confirmed HER2-positive cancer, as demonstrated by either fresh biopsy or ctDNA HER2-expression, with confirmed ORR of 48.9% and mDOR of 15.7 months vs. 24.5% ORR and mDOR of 9.1 months in the control group, and a PFS Hazard Ratio of 0.64Company to host conference call and investor webcast today at 1:00 PM PT/4:00 PM ET SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology

      1/23/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hemrajani Rekha bought $46,404 worth of shares (30,000 units at $1.55), increasing direct ownership by 1,000% to 33,000 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      12/4/24 4:17:28 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

      4/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      6/24/24 9:00:55 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      6/17/24 7:29:53 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows: Format: Fireside Chat Date: Thursday, June 5, 2025Time: 1:25 PM ETLocation: New York, NYWebcast link: Available here The live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology's website at www.alxoncology.com under the Events section of the Even

      5/30/25 8:00:21 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

      - A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent IND clearance from U.S. FDA, ALX2004 will enter clinical studies mid-year 2025 with initial safety data anticipated in 1H 2026 - Trials evaluating the Company's lead investigational therapy, CD47-blocker evorpacept, in breast and colorectal cancers planned to initiate in mid-2025 with multiple key inflection points from evorpacept and ALX2004 development programs anticipated in 2026 SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSW

      5/20/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

      SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company's potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration e

      5/13/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 7:22:54 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 6:58:27 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 3:02:41 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Leadership Updates

    Live Leadership Updates

    See more
    • ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

      Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operationsDr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experienceDr. Takimoto brings a distinguished track record in oncology and drug development with 17 years of industry experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced the appointmen

      1/22/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, announced today the appointment of Alan Sandler, M.D., as Chief Medical Officer. "Dr. Sandler's breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives," said Jason Lettmann, Chief Executive Officer at

      11/14/24 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "Our team continues to make significant progress in the advancement of our evorpacept development pipeline across multiple oncology indications," said Jason Lettmann, Chief Executive Officer of ALX Oncology. "Data readouts across our Phase 1 and 2 clinical trials highlight the potential of evorpacept as a disruptive therapy in combination with anti

      8/8/24 4:05:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ALX Oncology upgraded by Jefferies with a new price target

      Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $3.00 from $2.00 previously

      3/6/25 7:17:16 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology downgraded by Jefferies with a new price target

      Jefferies downgraded ALX Oncology from Buy to Hold and set a new price target of $2.00 from $12.00 previously

      12/19/24 7:28:17 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology downgraded by Stifel with a new price target

      Stifel downgraded ALX Oncology from Buy to Hold and set a new price target of $14.00 from $10.00 previously

      3/8/24 7:21:35 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care